Y-mAbs Therapeutics' (YMAB) CEO Claus Moller on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/15/19
Y-mAbs Therapeutics: Impressive Data In Multiple Oncology Indications, Regulatory Submissions LoomSeeking Alpha • 03/10/19